Scholarlink

<p><i>Cronobacter sakazakii</i> is an opportunistic foodborne pathogen causing intestinal and extra-intestinal diseases in humans, especially young children, and is regarded as one of the main concerns in public health. <i>Saccharomyces boulardii</i> is a well-known probiotic yeast widely used to treat and prevent antibiotic-associated diarrheal infections in infants and neonates. This study evaluated the preventive effects and potential of probiotic <i>S. boulardii</i> against <i>C. sakazakii</i> intestinal infections in humans. Viability, bacterial virulence factor, cellular pro-inflammatory gene expression, and nanomechanical properties of the cytoplasmic membrane of caco-2 cells were evaluated using MTT, real-time PCR, and AFM methods, respectively. Using histopathological analysis, <i>S. boulardii</i> treatment was evaluated on infected newborn C57 BL/6 mice. We found that <i>S. boulardii</i> inoculation significantly (<i>P</i> &lt; 0.05) increased the viability and downregulated the cellular pro-inflammatory genes (<i>IL-8</i> and <i>NFkB</i>) and bacterial virulence factor genes (<i>ompA</i> and <i>hfq</i>) in infected intestinal cells while also decreasing the morphological alterations. We also observed that <i>S. boulardii</i> treatment reduced the intestinal damage induced by <i>C. sakazakii</i> infection. In conclusion, our findings demonstrate that <i>S. boulardii</i> effectively protects against <i>C. sakazakii</i> infections. This probiotic yeast holds promise as a potential preventive and therapeutic agent for intestinal diseases associated with <i>C. sakazakii</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Probiotic Saccharomyces boulardii Against Cronobacter sakazakii Infection: In Vitro and In Vivo Studies

  • 期刊论文

  • 发表日期：

    2025年3月21日

查看全文
  • Samaneh Allahyari,
  • Babak Pakbin,
  • Shaghayegh Pishkhan Dibazar,
  • Neda Karami,
  • Gholamreza Hamidian,
  • Leila Zolghadr,
  • Reza Ovissipour,
  • Razzagh Mahmoudi

摘要

Cronobacter sakazakii is an opportunistic foodborne pathogen causing intestinal and extra-intestinal diseases in humans, especially young children, and is regarded as one of the main concerns in public health. Saccharomyces boulardii is a well-known probiotic yeast widely used to treat and prevent antibiotic-associated diarrheal infections in infants and neonates. This study evaluated the preventive effects and potential of probiotic S. boulardii against C. sakazakii intestinal infections in humans. Viability, bacterial virulence factor, cellular pro-inflammatory gene expression, and nanomechanical properties of the cytoplasmic membrane of caco-2 cells were evaluated using MTT, real-time PCR, and AFM methods, respectively. Using histopathological analysis, S. boulardii treatment was evaluated on infected newborn C57 BL/6 mice. We found that S. boulardii inoculation significantly (P < 0.05) increased the viability and downregulated the cellular pro-inflammatory genes (IL-8 and NFkB) and bacterial virulence factor genes (ompA and hfq) in infected intestinal cells while also decreasing the morphological alterations. We also observed that S. boulardii treatment reduced the intestinal damage induced by C. sakazakii infection. In conclusion, our findings demonstrate that S. boulardii effectively protects against C. sakazakii infections. This probiotic yeast holds promise as a potential preventive and therapeutic agent for intestinal diseases associated with C. sakazakii.